鈉-葡萄糖共轉(zhuǎn)運(yùn)蛋白2抑制劑類藥物在心力衰竭患者合并心律失常中的研究進(jìn)展

[Abstract]With the widespread clinical application of sodium-glucose cotransporter 2 inhibitors （SGLT2i）， an increasing numberofstudieshave highlightedtheirbeneficialefects notonlyinbloodglucosecontrolindiabetic patients but also in providing significant cardiovascular protection in non-diabetic individuals，particularly those with heartfailure.These drugscansignificantlyreduce theoccuenceof arrhythmias through multiple mechanisms. Currently marketedSGLT2i drugs，including Dapagliflozin，Empagliflozin，andCanagliflozin，havebeenreportedto be beneficial inarrhythmic patients.Their mechanisms of action involvemodulationof ionchannels，enhancement of cardiacenergyutilization eficiency，andreductionoffatyacidaccumulation，among others.Thisreviewaims to analyze theroleofSGLT2i intheprevention and treatmentof arhythmiasand their underlying mechanisms by reviewing the relevant literatureinrecent years，and to provideareference for future studiesto clarifythe potential applications of SGLT2i in various arrhythmia types.

[Keywords] Sodium-glucose cotransporter 2 inhibitorsHeart failureArrhythmia

First-author'saddress：Departmentof Cardiology，Jinan ThirdPeople'sHospital，Jinan250100 China

doi：10.3969/j.issn.1674-4985.2025.21.040

心力衰竭（heartfailure，HF）作為一種較為常見的臨床綜合征，常由各種心臟疾病引起，主要特征表現(xiàn)為心臟泵血功能下降，并伴隨多種心臟電生理異常，這其中，以心律失常，尤其是室性心律失常（ventriculararrhythmia，VA）為最常見的一種并發(fā)癥，同時(shí)，其也是導(dǎo)致心源性猝死（suddencardiacdeath，SCD）和住院率增加的重要因素[-2]。（剩余8764字）